Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Acuta Capital Partners LLC

Acuta Capital Partners LLC boosted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 165.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 771,958 shares of the company's stock after acquiring an additional 481,458 shares during the period. Trevi Therapeutics comprises 3.2% of Acuta Capital Partners LLC's investment portfolio, making the stock its 11th biggest holding. Acuta Capital Partners LLC owned about 1.00% of Trevi Therapeutics worth $3,180,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Summit Investment Advisors Inc. increased its holdings in Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after buying an additional 2,894 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Trevi Therapeutics during the 4th quarter worth about $49,000. China Universal Asset Management Co. Ltd. purchased a new stake in Trevi Therapeutics during the fourth quarter worth approximately $67,000. Jump Financial LLC purchased a new stake in Trevi Therapeutics during the fourth quarter worth approximately $89,000. Finally, Invesco Ltd. boosted its holdings in Trevi Therapeutics by 21.2% in the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company's stock valued at $97,000 after purchasing an additional 4,133 shares in the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Needham & Company LLC restated a "buy" rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a research note on Tuesday, April 8th. Oppenheimer lifted their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. D. Boral Capital reiterated a "buy" rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and issued a $12.50 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Finally, Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their target price for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Trevi Therapeutics presently has a consensus rating of "Buy" and an average price target of $17.56.

Trevi Therapeutics Trading Up 2.7 %

Shares of TRVI traded up $0.18 during midday trading on Wednesday, reaching $6.76. 281,723 shares of the company were exchanged, compared to its average volume of 1,149,073. Trevi Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $7.39. The company has a market cap of $674.78 million, a price-to-earnings ratio of -15.39 and a beta of 0.62. The stock has a 50-day moving average price of $6.02 and a 200-day moving average price of $4.46.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. Equities research analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at approximately $1,403,599.54. This represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.37% of the stock is currently owned by company insiders.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.